SCHEMBL6813416

SCHEMBL6813416

O=C1CCCC[C@H](C(=O)O)N1

nearest known ligand 0.50

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MME P08473 14/20 0.44
ACE P12821 9/20 0.43
CAD P27708 1/20 0.42
ECE1 P42892 1/20 0.42
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6814128 1.00 MME (0.44) MMEACECADECE1KDM4E
SCHEMBL6501628 1.00 MME (0.44) MMEACECADECE1KDM4E
SCHEMBL4903224 0.98 MME (0.46) MMEACECADECE1KDM4E
SCHEMBL18576543 0.98 MME (0.46) MMEACECADECE1KDM4E
SCHEMBL15134405 0.98 MME (0.46) MMEACECADECE1KDM4E
SCHEMBL20367630 0.98 MME (0.46) MMEACECADECE1KDM4E
SCHEMBL630497 0.94 CAD (0.43) MMEACECAD
SCHEMBL3625069 0.94 CAD (0.43) MMEACECAD
SCHEMBL2344195 0.94 CAD (0.43) MMEACECAD
SCHEMBL3258686 0.88 FKBP5 (0.52) MMEACEECE1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1054996-B1 PROCESS FOR THE ENZYMATIC RESOLUTION OF LACTAMS SEARLE & CO (US) 2004-01-28 EP disclosed
US-6638758-B2 Separating enantiomeric lactam esters by selective hydrolyzing one enantiomer by contact with a biocatalyst, such as an enzyme or a microorganism and separating the hydrolysis product from the unreacted lactam esters. G.D. SEARLE & CO. 2003-10-28 US disclosed
US-20010055798-A1 Process for the enzymatic resolution of lactams G.D. SEARLE & CO. 2001-12-27 US disclosed
US-6277626-B1 LACTAM ESTERS ARE CONTACTED WITH A BIOCATALYST, SUCH AS ENZYME OR A MICROORGANISM, IN SOLUTION WHEREIN ONLY ONE ENANTIOMER IS SELECTIVELY HYDROLYZED TO GIVE OPTICALLY ACTIVE ISOMER OF CORRESPONDING ACID; SEPARATING HYDROLYSIS PRODUCT G.D. SEARLE & CO. 2001-08-21 US disclosed
EP-1054996-A1 PROCESS FOR THE ENZYMATIC RESOLUTION OF LACTAMS G.D. SEARLE & CO. (US) 2000-11-29 EP disclosed
WO-1999041405-A1 PROCESS FOR THE ENZYMATIC RESOLUTION OF LACTAMS G.D. SEARLE & CO. (US) 1999-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010055798-A1 Process for the enzymatic resolution of lactams MGAM, SRR, APEH MME 613/4885ACE 69/4885CAD 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.